
Releases
TrueLab Licenses Two Immunology Assets to Bionyra in $985 Million Deal
Ningbo-based TrueLab Biopharmaceutical has signed an exclusive global licensing agreement with the newly launched Bionyra Pharma for two next-generation antibody candidates. The deal, valued at up to $985 million, grants Bionyra rights to develop and commercialize the TL-001 and TL-003 programs outside of Greater China.


























